GLP-1 'weird side effects': hype vs. what studies show

What did @realdrbae actually say?

Dr. Welt claims GLP-1 medications produce a range of unexpected behavioral side effects beyond weight loss. Specifically, he says patients reported alcohol "didn't hit the same way," leading some to drink less or quit entirely. He goes further, claiming these drugs also reduced interest in smoking, vaping, nail biting, and online shopping. He mentions an addiction specialist in his practice is actively using semaglutide with addiction patients.

The alcohol and smoking claims have at least some scientific backing. The nail biting and online shopping claims do not. That distinction matters, and the video never makes it. Lumping together studied phenomena with anecdotal observations is how medical misinformation spreads even when the speaker has legitimate credentials.

Does the science back this up?

For alcohol and substance use, yes, partially, and the evidence is genuinely interesting. For nail biting and online shopping, no peer-reviewed evidence exists.

A 2023 randomized controlled trial by Klausen et al. published in JCI Insight found that semaglutide significantly reduced alcohol consumption in alcohol-use disorder patients compared to placebo. A 2022 preclinical review by Leggio and Hendershot in Neuropsychopharmacology outlined plausible dopaminergic mechanisms: GLP-1 receptors are expressed in reward-related brain regions including the nucleus accumbens and ventral tegmental area, which process cravings for drugs, food, and other reinforcing stimuli. A 2024 observational study using insurance claims data by Anekwe et al. in Nature Communications found associations between GLP-1 use and lower rates of substance use disorder diagnoses.

So the addiction angle has real signal. But "real signal" is not the same as proven treatment, and a TikTok video to 282,000 viewers probably should not blur that line.

What did they get wrong (or right)?

Credit where it is due: the core claim that GLP-1 drugs affect reward pathways and may reduce alcohol and nicotine use is biologically plausible and supported by emerging data. Describing it as a "side effect" is actually accurate framing since these behavioral changes were not the primary indication in most trials.

What Dr. Welt gets wrong is scale and specificity. Calling nail biting and online shopping reductions credible drug effects puts them on equal footing with findings from controlled trials. They are not. These are anecdotes from his patient panel, which is fine to mention but requires a clear disclaimer. He offers none. The phrase "hundreds of patients" sounds like clinical data. It is not. No control group, no systematic measurement, no publication.

Describing himself as "TikTok's GLP1 expert" is a branding choice, not a clinical credential, and it primes viewers to accept claims uncritically. That is worth naming.

What should you actually know?

The most honest summary: GLP-1 medications appear to influence reward and craving pathways in ways that go beyond appetite suppression, and researchers are actively investigating this. That is genuinely exciting. Clinical trials specifically examining semaglutide for alcohol use disorder are underway, and early results are promising.

But promising is not proven. Using semaglutide off-label to treat addiction is not a standard of care, and the doses and titration schedules studied for addiction may differ from those used in weight management. If you are on a GLP-1 drug and notice changes in cravings or drinking habits, that is worth discussing with your prescriber. It is not a reason to self-adjust your medication or assume the drug is treating an underlying addiction disorder.

The nail biting and online shopping framing is the kind of content that makes doctors look unserious. It also risks making patients attribute any behavioral change to their medication, which can obscure real clinical issues that deserve attention.